A Phase II, Single Arm Study of Chemoimmunotherapy for the Treatment of Men with Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
February 23, 2021
End Date
March 14, 2026
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
February 23, 2021
End Date
March 14, 2026